Literature DB >> 15057661

Prokinetics in the treatment of acute intestinal pseudo-obstruction.

Roberto De Giorgio1, Vincenzo Stanghellini, Giovanni Barbara, Stefani Guerrini, Andrea Lioce, Valentina Vasina, Marcello Tonini, Bruno Cola, Roberto Corinaldesi, Fabrizio De Ponti.   

Abstract

Acute colonic pseudo-obstruction (Ogilvie's syndrome) is characterized by an acute obstruction of the large bowel that is unrelated to mechanical causes. The evidence that cholinesterase inhibitors are effective in relieving acute colonic pseudo-obstruction raised interest in the pharmacological management of this condition. This review analyzes the pharmacological treatment of patients with Ogilvie's syndrome. Intravenous neostigmine is the best pharmacological treatment, leading to rapid colonic decompression. New colokinetic agents, including 5-HT(4) receptor agonists and motilides, may represent other useful therapeutic options for Ogilvie's syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057661

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  3 in total

Review 1.  [Cholinesterase inhibitors. Importance in anaesthesia, intensive care medicine, emergency medicine and pain therapy].

Authors:  S Kleinschmidt; S Ziegeler; C Bauer
Journal:  Anaesthesist       Date:  2005-08       Impact factor: 1.041

2.  Neostigmine treatment protocols applied in acute colonic pseudo-obstruction disease: A retrospective comparative study.

Authors:  Ömür İlban; Faruk Çiçekçi; Jale Bengi Çelik; Mehmet Ali Baş; Ateş Duman
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

3.  Polypyridylruthenium(II) complexes exert anti-schistosome activity and inhibit parasite acetylcholinesterases.

Authors:  Madhu K Sundaraneedi; Bemnet A Tedla; Ramon M Eichenberger; Luke Becker; Darren Pickering; Michael J Smout; Siji Rajan; Phurpa Wangchuk; F Richard Keene; Alex Loukas; J Grant Collins; Mark S Pearson
Journal:  PLoS Negl Trop Dis       Date:  2017-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.